First-Line Immune Tx: An Option in V600K-Mutant Melanoma

Posted On: Jan 14, 2019   |   Posted By: MedPageToday

Higher mutational load in BRAF-mutant V600K genotype translates into better response to anti-PD1 immunotherapy than targeting BRAF/MEK

Continue reading ...